Profound Medical and Telix Pharmaceuticals Sign Agreement for Prostate Cancer Diagnosis and Treatment Education
TLX Telix Pharmaceuticals Ltd ADR
$11.01 -0.99%
View chart & analysis → 
- 1Profound Medical and Telix Pharmaceuticals have signed a joint education agreement to promote how prostate cancer diagnostic imaging supports treatment planning.
- 2Given that 85% of prostate cancers are multifocal, this collaboration focuses on increasing understanding among medical professionals.
- 3CEO and Chairman Arun Menawat stated that this agreement will strengthen the relationship with Telix and expand engagement with medical experts.
So what's the key point?
The two companies have decided to promote better ways to diagnose and treat prostate cancer. This collaboration will increase awareness among medical professionals and strengthen the relationship between the two companies.
Source InvestorsHub +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.